Key facts
- Durin Life Sciences’s last known valuation is $10.0M (Dec 2019).
- It has raised $14.3M across 2 recorded rounds; the latest was Early Stage VC ($5.5M) in Mar 2021.
- Notable investors include Breakthrough Diagnostic LLC, Foundation Venture Capital Group, Michael J. Fox Foundation, Rowan University.
- Durin Life Sciences has filed 2 Form Ds with the SEC, most recently Jul 2025 ($6.2M sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Durin Life Sciences
Funding rounds
2 roundsAbout Durin Life Sciences
Operator of a diagnostic tests development company intended to measure certain autoantibodies in serum associated with neurodegenerative diseases. The company's technology helps in the detection of Alzheimer's disease using blood and is also used for the detection of Alzheimer's and Parkinson's disease, enabling surgeons to detect signs of a particular disease and securely diagnose a patient's illness.
- Sector
- Healthcare
- HQ
- Stratford, NJ, United States
- Founded
- 2010
- Employees
- 15
- Website
- durinlifesciences.com/
- Ownership
- Privately Held (backing)
Durin Life Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Durin Life Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Durin Life Sciences in its N-PORT filings yet. We sweep new filings monthly.